Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Penumbra $14.5 billion sale to Boston Scientific
We are advising Penumbra on the transaction
Roche Holdings $1.9 billion notes offering
We advised Roche on the offering comprising three tranches of notes
bit.bio $50 million Series C equity financing
We are advising the company on the funding round
Aktis Oncology $318 million IPO
This is the first biotech IPO of 2026
Beacon Therapeutics $75 million Series C financing round
We advised Forbion on its participation in the financing round
W. L. Gore & Associates acquisition of Conformal Medical
We are advising Gore on the transaction
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
Trial victory for Magnolia Medical in patent infringement litigation
We secured a unanimous jury verdict against Magnolia’s sole competitor in the market for initial specimen diversion devices
PegBio HK$300 million placement of shares
We advised PegBio on the placement of new shares
GSK strategic collaboration with CAMP4 Therapeutics
We advised GSK on the transaction